Indirubin Treatment of Lipopolysaccharide-Induced Mastitis in a Mouse Model and Activity in Mouse Mammary Epithelial Cells

Indirubin is a Chinese medicine extracted from indigo and known to be effective for treating chronic myelogenous leukemia, neoplasia, and inflammatory disease. This study evaluated the in vivo anti-inflammatory activity of indirubin in a lipopolysaccharide- (LPS-) induced mouse mastitis model. The i...

Full description

Saved in:
Bibliographic Details
Main Authors: Jin-lun Lai (Author), Yu-hui Liu (Author), Yong-chong Peng (Author), Pan Ge (Author), Chen-fei He (Author), Chang Liu (Author), Ying-yu Chen (Author), Ai-zhen Guo (Author), Chang-min Hu (Author)
Format: Book
Published: Hindawi Limited, 2017-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b8ca2c484f3f43cd9abf09b83ba67b4b
042 |a dc 
100 1 0 |a Jin-lun Lai  |e author 
700 1 0 |a Yu-hui Liu  |e author 
700 1 0 |a Yong-chong Peng  |e author 
700 1 0 |a Pan Ge  |e author 
700 1 0 |a Chen-fei He  |e author 
700 1 0 |a Chang Liu  |e author 
700 1 0 |a Ying-yu Chen  |e author 
700 1 0 |a Ai-zhen Guo  |e author 
700 1 0 |a Chang-min Hu  |e author 
245 0 0 |a Indirubin Treatment of Lipopolysaccharide-Induced Mastitis in a Mouse Model and Activity in Mouse Mammary Epithelial Cells 
260 |b Hindawi Limited,   |c 2017-01-01T00:00:00Z. 
500 |a 0962-9351 
500 |a 1466-1861 
500 |a 10.1155/2017/3082805 
520 |a Indirubin is a Chinese medicine extracted from indigo and known to be effective for treating chronic myelogenous leukemia, neoplasia, and inflammatory disease. This study evaluated the in vivo anti-inflammatory activity of indirubin in a lipopolysaccharide- (LPS-) induced mouse mastitis model. The indirubin mechanism and targets were evaluated in vitro in mouse mammary epithelial cells. In the mouse model, indirubin significantly attenuated the severity of inflammatory lesions, edema, inflammatory hyperemia, milk stasis and local tissue necrosis, and neutrophil infiltration. Indirubin significantly decreased myeloperoxidase activity and downregulated the production of tumor necrosis factor-α, interleukin-1β (IL-1β), and IL-6 caused by LPS. In vitro, indirubin inhibited LPS-stimulated expression of proinflammatory cytokines in a dose-dependent manner. It also downregulated LPS-induced toll-like receptor 4 (TLR4) expression and inhibited phosphorylation of LPS-induced nuclear transcription factor-kappa B (NF-κB) P65 protein and inhibitor of kappa B. In addition to its effect on the NF-κB signaling pathway, indirubin suppressed the mitogen-activated protein kinase (MAPK) signaling by inhibiting phosphorylation of extracellular signal-regulated kinase (ERK), P38, and c-jun NH2-terminal kinase (JNK). Indirubin improved LPS-induced mouse mastitis by suppressing TLR4 and downstream NF-κB and MAPK pathway inflammatory signals and might be a potential treatment of mastitis and other inflammatory diseases. 
546 |a EN 
690 |a Pathology 
690 |a RB1-214 
655 7 |a article  |2 local 
786 0 |n Mediators of Inflammation, Vol 2017 (2017) 
787 0 |n http://dx.doi.org/10.1155/2017/3082805 
787 0 |n https://doaj.org/toc/0962-9351 
787 0 |n https://doaj.org/toc/1466-1861 
856 4 1 |u https://doaj.org/article/b8ca2c484f3f43cd9abf09b83ba67b4b  |z Connect to this object online.